Clarity
Do they understand what you do?
Strong15 of 15
15 could name what kind of product this is, unprompted.
Saved report, kept for 60 days — expires in 60 days. Re-opening it is free.
01
Your verdict
Relevance
Can they tell what it solves, and who it's for?
Strong15 of 1515 could quickly tell what problem it solves and who it is for.
Value
Do they actually want it?
Strong15 of 1515 would take a meeting to learn more.
Differentiation
Fix firstIs there a reason to pick you over the alternatives?
Mixed10 of 1510 could name a reason to pick you over a similar option.
See what they thought you were
Your page describes: Veeva implementation consulting. They said:
- 1×Veeva Vault implementation/consulting servicesmatches
14 couldn't name one; 1 got it right.
Four separate measures, not stages: all 15 personas answered all four questions. Each square is one persona.
Additional signalBrand alignment15 of 15StrongShow finding ▸
Three respondents flagged voice problems: pharma vocabulary despite medtech positioning, a hero section that reads like agency copywriting, and opening phrases that are abstract with no concrete activities or verbs. Not one of the four layers, and it does not affect the scores above or the order to fix them in.
These are 15 simulated buyers. Want 15 real ones?
Test with humans02
Fix these firstFix these first
Three edits, in the order that matters.
The first is on your weakest layer, the second on the next, the third on the layer the most buyers had a problem with. Each says what to change on the page and why, with one simulated answer behind it.
Add a client proof block under the stats row with named or redacted engagements.
Why: "25+ Veeva Engagements" and "10+ Specialist Delivery Partnerships" are numbers with no engagement behind them, so a buyer cannot verify anyone has done this work. Add two or three short engagement summaries naming the segment, Vault suite, scale and outcome…
6 of 15 raised this
“But it would rule them out just as fast if I couldn't verify it — there's no case study, no named client, no "we did X submissions for…” Show full quote
“But it would rule them out just as fast if I couldn't verify it — there's no case study, no named client, no "we did X submissions for a 300-person medtech" to back it up, so right now it's a claim, not proof.”
RIM Lead, Medical Devices · 201-500 employeessimulated Moves DifferentiationProof next to the claimAdd a line under the hero naming the roles you work with.
Why: A reader has to reconstruct the audience from Vault jargon and the FAQ. State plainly that you work with RIM, QA and IT leads mid-migration or running a live Vault.
2 of 15 raised this
“I'd want to see our region named — something like "we work with APAC biotechs" or a client logo/geography reference — plus a line acknowledging multi-site or cross-border…” Show full quote
“I'd want to see our region named — something like "we work with APAC biotechs" or a client logo/geography reference — plus a line acknowledging multi-site or cross-border submission complexity”
Regulatory Operations Manager, Biotechnology · 51-200 employeessimulated Moves ClarityName the audienceAdd price range and a sample output link under the platform assessment.
Why: The assessment is the low-risk way in, but the page never says what it costs or what you hand over. Add a starting price or duration and a link to a redacted sample report.
Moves ValueAnswer the live objection
Keep these · 3
These landed. Keep the wording when you edit around it.
- Keep · Clarity
The Vault-only specialist positioning is understood and repeated back
“Most technology consultancies have a Veeva practice... That is not how we work”
Clinical Operations Manager, Pharmaceutical · 501-1000 employeessimulated - Keep · Relevance
The configuration-drift failure story lands as a recognised problem
“The "What We Do" section and the line "A misconfigured Vault doesn't fail immediately — it fails six months later in a workflow that contradicts your SOPs" tells…” Show full quote
“The "What We Do" section and the line "A misconfigured Vault doesn't fail immediately — it fails six months later in a workflow that contradicts your SOPs" tells me exactly the problem — configuration drift and validation gaps that bite you later, which is literally my situation.”
Regulatory Operations Manager, Biotechnology · 51-200 employeessimulated - Keep · Differentiation
The Vault Domain Coverage grid is the strongest differentiation asset on the page
“The thing that would actually tip me toward them over a generalist competitor is the specific claim "25+ Veeva Engagements" combined with the domain list under "Vault Domain…” Show full quote
“The thing that would actually tip me toward them over a generalist competitor is the specific claim "25+ Veeva Engagements" combined with the domain list under "Vault Domain Coverage" — naming actual modules (Vault QualityDocs, Vault RIM, Vault Safety Inbox, TMF Bot, etc.) and compliance specifics like 21 CFR Part 11 and EU Annex 11 by name is a concrete signal they've actually been in these systems”
Regulatory Operations Manager, Biotechnology · 51-200 employeessimulated
03
All recommendations
Differentiation
Mixed10 of 15Moves DifferentiationProof next to the claim
Name a biotech and a medtech engagement beside the "pharma, biotech, medtech" claim.
Why: The page claims medtech and biotech coverage but every example and term reads pharma. Add one line each describing a device or biotech client's situation and what was delivered.
6 of 15 raised this
“But it would rule them out just as fast if I couldn't verify it — there's no case study, no named client, no "we did X submissions for…” Show full quote
“But it would rule them out just as fast if I couldn't verify it — there's no case study, no named client, no "we did X submissions for a 300-person medtech" to back it up, so right now it's a claim, not proof.”
Moves DifferentiationShow the product early
Move the Vault Domain Coverage grid above the End-to-End Delivery section.
Why: The module-level grid is the clearest evidence of real Vault experience, but it sits below several paragraphs of claims about depth over breadth. Lift it near the top so a reader checking their own stack finds it before they leave.
6 of 15 raised this
“But it would rule them out just as fast if I couldn't verify it — there's no case study, no named client, no "we did X submissions for…” Show full quote
“But it would rule them out just as fast if I couldn't verify it — there's no case study, no named client, no "we did X submissions for a 300-person medtech" to back it up, so right now it's a claim, not proof.”
Clarity
Strong15 of 15Relevance
Strong15 of 15No specific edits needed here — this layer held up.
Value
Strong15 of 15Brand alignment
Strong15 of 15Moves Brand alignmentLead with the use case
Rewrite the hero headline to state the job, cutting "Not just as a platform. As a practice."
Why: The opening line is broken and abstract, with no activity or verb a buyer recognises. Replace it with what you do for whom, such as implementing and running Vault QMS, RIM and QualityDocs for regulated life sciences teams.
2 of 15 raised this
“They sell to mid-size pharma/biotech primarily, with medtech as a secondary afterthought — the language defaults to "regulated environment," SOPs, QA sign-off, inspection readiness, which is pharma-flavored vocabulary…” Show full quote
“They sell to mid-size pharma/biotech primarily, with medtech as a secondary afterthought — the language defaults to "regulated environment," SOPs, QA sign-off, inspection readiness, which is pharma-flavored vocabulary even when they nod to medtech.”
04
Buyer evidence
Biggest risks
A deliberately adversarial read of the same answers. Each claim was checked back against what the personas said and dropped if nothing supported it.
- high
The page converts nobody because it asks for trust it never earns.
Ten respondents cited unnamed engagements, missing client references and unverified partnership counts as action blockers, with several naming the exact proof they needed — a biotech or medical device client at comparable scale. Comprehension gains are…
- high
Positioning comprehension is being mistaken for persuasion.
Six respondents repeated back the Vault-only specialist positioning and five recognised the configuration-drift failure story, yet ten still said missing proof stops them acting. Being understood and being believed are different outcomes, and only the first…
- high
The one low-friction conversion path on the page is unusable as written.
Three respondents named the standalone platform assessment as a credible way to test the firm, but two immediately flagged missing pricing and sample output. A de-risking offer with undisclosed terms reintroduces the risk it was meant to remove.
- medium
The strongest asset on the page is a table, not an argument.
Four respondents named the Vault Domain Coverage grid as the top differentiator, with one valuing it because it could be checked against their own stack. The page's credibility rests on a competitor-copyable inventory rather than evidence of outcomes.
- medium
The copy does not know which market it is addressing.
Three respondents flagged pharma vocabulary despite medtech positioning, agency-style hero copy, and abstract openings without concrete verbs. Separately, the target persona had to be reconstructed from jargon and the FAQ, with no explicit audience statement.
- medium
Voice credibility is concentrated in deep-page sections most readers never reach.
Two respondents found genuine operator knowledge of QA/QMS and RIM failure modes, while three flagged the hero and opening phrases as agency copywriting with no concrete activities. The weakest writing occupies the highest-traffic position.
Differentiation
The absence of named clients and case studies is the single biggest blocker
6 of 15
“But it would rule them out just as fast if I couldn't verify it — there's no case study, no named client, no "we did X submissions for…” Show full quote
“But it would rule them out just as fast if I couldn't verify it — there's no case study, no named client, no "we did X submissions for a 300-person medtech" to back it up, so right now it's a claim, not proof.”
RIM Lead, Medical Devices · 201-500 employeessimulated See all 10 comments
“before I'd go further I'd want named biotech clients at our scale and maybe a reference I can call, since right now it's their word on "25+ Veeva…” Show full quote
“before I'd go further I'd want named biotech clients at our scale and maybe a reference I can call, since right now it's their word on "25+ Veeva Engagements" with no names attached.”
IT Business Partner, Biotechnology · 1001-5000 employeessimulated “The "25+ Veeva Engagements" and "10+ Specialist Delivery Partnerships" numbers have no backup, so I'd treat those as marketing until proven.”
Quality Systems Manager, Medical Devices · 51-200 employeessimulated “before I'd take the call I'd want them to back up the "25+ Veeva Engagements" and "10+ Specialist Delivery Partnerships" with actual client names or case studies in…” Show full quote
“before I'd take the call I'd want them to back up the "25+ Veeva Engagements" and "10+ Specialist Delivery Partnerships" with actual client names or case studies in Medical Devices specifically, not just pharma/biotech.”
Quality Systems Manager, Medical Devices · 51-200 employeessimulated “"25+ Veeva Engagements" and "10+ Specialist Delivery Partnerships" are unverified numbers with no named client, no case study, no before/after”
Clinical Operations Manager, Pharmaceutical · 501-1000 employeessimulated “What I'd still need in that meeting is proof — an actual redacted validation pack or a reference client in a QMS of similar scale and complexity —…” Show full quote
“What I'd still need in that meeting is proof — an actual redacted validation pack or a reference client in a QMS of similar scale and complexity — before I'd move past evaluation into a signed engagement”
QA/QMS Manager, Pharmaceutical · 201-500 employeessimulated “seeing "Vault QualityDocs, Vault QMS, 21 CFR Part 11, CAPA, Deviation Management" and the Clinical/Safety/Regulatory breakdowns tells me they actually know the terrain, not just the platform name.…” Show full quote
“seeing "Vault QualityDocs, Vault QMS, 21 CFR Part 11, CAPA, Deviation Management" and the Clinical/Safety/Regulatory breakdowns tells me they actually know the terrain, not just the platform name. But what would rule them out, or at least stall me, is the total absence of named clients”
IT Business Partner, Biotechnology · 1001-5000 employeessimulated “I'd want a named client profile up top — "we work with QA and regulatory teams at 200-500 person pharma companies running paper or hybrid QMS moving to…” Show full quote
“I'd want a named client profile up top — "we work with QA and regulatory teams at 200-500 person pharma companies running paper or hybrid QMS moving to Vault" — instead of generic "life sciences" language, plus the SOP/validation failure line moved to the first screen”
QA/QMS Manager, Pharmaceutical · 201-500 employeessimulated “if a competitor shows the same module list plus one named Medical Devices client reference or a validation deliverable sample, they win. Right now "25+ Veeva Engagements" with…” Show full quote
“if a competitor shows the same module list plus one named Medical Devices client reference or a validation deliverable sample, they win. Right now "25+ Veeva Engagements" with no names attached is a reason to rule this one out against a competitor who shows their work, not just claims it.”
Quality Systems Manager, Medical Devices · 51-200 employeessimulated “I have no case study, no named client, no reference I can call, so it's still a story, not evidence.”
Regulatory Operations Manager, Biotechnology · 501-1000 employeessimulated The Vault Domain Coverage grid is the strongest differentiation asset on the page
4 of 15 · what worked
“The thing that would actually tip me toward them over a generalist competitor is the specific claim "25+ Veeva Engagements" combined with the domain list under "Vault Domain…” Show full quote
“The thing that would actually tip me toward them over a generalist competitor is the specific claim "25+ Veeva Engagements" combined with the domain list under "Vault Domain Coverage" — naming actual modules (Vault QualityDocs, Vault RIM, Vault Safety Inbox, TMF Bot, etc.) and compliance specifics like 21 CFR Part 11 and EU Annex 11 by name is a concrete signal they've actually been in these systems”
Regulatory Operations Manager, Biotechnology · 51-200 employeessimulated See all 4 comments
“The "Vault Domain Coverage" grid is the one thing that would pull me towards a call — it names actual sub-modules like Vault RIM, eCTD v3 & v4,…” Show full quote
“The "Vault Domain Coverage" grid is the one thing that would pull me towards a call — it names actual sub-modules like Vault RIM, eCTD v3 & v4, IDMP, Global Registration Tracking, rather than just saying "regulatory experience."”
RIM Lead, Medical Devices · 201-500 employeessimulated “"25+ Veeva Engagements" and "10+ Specialist Delivery Partnerships" are unverified numbers with no named client, no case study, no before/after”
Clinical Operations Manager, Pharmaceutical · 501-1000 employeessimulated “The "Vault Domain Coverage" grid listing specific modules by suite — Vault QMS, Vault RIM, Vault eTMF, Vault Safety, Vault PromoMats — is the one thing that could…” Show full quote
“The "Vault Domain Coverage" grid listing specific modules by suite — Vault QMS, Vault RIM, Vault eTMF, Vault Safety, Vault PromoMats — is the one thing that could tip it toward them, because it's specific enough to check against our own stack instead of vague "life sciences expertise" talk.”
Quality Systems Manager, Medical Devices · 51-200 employeessimulated
Clarity
The Vault-only specialist positioning is understood and repeated back
5 of 15 · what worked
“Most technology consultancies have a Veeva practice... That is not how we work”
Clinical Operations Manager, Pharmaceutical · 501-1000 employeessimulated See all 6 comments
“They're a specialist consulting firm for Veeva Vault implementations — basically a niche systems integrator that does implementation, validation (IQ/OQ/PQ), release management, and ongoing managed support for companies…” Show full quote
“They're a specialist consulting firm for Veeva Vault implementations — basically a niche systems integrator that does implementation, validation (IQ/OQ/PQ), release management, and ongoing managed support for companies running Vault in regulated pharma/biotech environments.”
IT Business Partner, Biotechnology · 1001-5000 employeessimulated “They're a consulting shop that specializes in Veeva Vault — implementation, migration, integration, and ongoing managed services (release management, admin, validation support) for life sciences companies running Vault's…” Show full quote
“They're a consulting shop that specializes in Veeva Vault — implementation, migration, integration, and ongoing managed services (release management, admin, validation support) for life sciences companies running Vault's Quality, Regulatory, Clinical, Safety, and Commercial suites.”
Quality Systems Manager, Medical Devices · 51-200 employeessimulated “the "Partnership Models" section (Consulting Engagements, Managed Services, Platform Partner, Expert On-Call) spells out the actual deliverable, which is more concrete than most of the marketing fluff above…” Show full quote
“the "Partnership Models" section (Consulting Engagements, Managed Services, Platform Partner, Expert On-Call) spells out the actual deliverable, which is more concrete than most of the marketing fluff above it”
QA/QMS Manager, Pharmaceutical · 201-500 employeessimulated “I picture a smallish, fairly young boutique — maybe 20-50 consultants, not a few hundred — built by people who came out of bigger Veeva implementation partners or…” Show full quote
“I picture a smallish, fairly young boutique — maybe 20-50 consultants, not a few hundred — built by people who came out of bigger Veeva implementation partners or life sciences IT and decided to specialise hard”
QA/QMS Manager, Pharmaceutical · 201-500 employeessimulated “They're a specialist consulting shop that implements, migrates, configures and then manages Veeva Vault for pharma/biotech/medtech companies — basically a Vault-only systems integrator plus managed services arm for…” Show full quote
“They're a specialist consulting shop that implements, migrates, configures and then manages Veeva Vault for pharma/biotech/medtech companies — basically a Vault-only systems integrator plus managed services arm for the regulated life sciences world.”
Regulatory Operations Manager, Biotechnology · 501-1000 employeessimulated The target persona is inferred from jargon rather than stated
2 of 15
“I'd want to see our region named — something like "we work with APAC biotechs" or a client logo/geography reference — plus a line acknowledging multi-site or cross-border…” Show full quote
“I'd want to see our region named — something like "we work with APAC biotechs" or a client logo/geography reference — plus a line acknowledging multi-site or cross-border submission complexity”
Regulatory Operations Manager, Biotechnology · 51-200 employeessimulated
Relevance
The configuration-drift failure story lands as a recognised problem
5 of 15 · what worked
“The "What We Do" section and the line "A misconfigured Vault doesn't fail immediately — it fails six months later in a workflow that contradicts your SOPs" tells…” Show full quote
“The "What We Do" section and the line "A misconfigured Vault doesn't fail immediately — it fails six months later in a workflow that contradicts your SOPs" tells me exactly the problem — configuration drift and validation gaps that bite you later, which is literally my situation.”
Regulatory Operations Manager, Biotechnology · 51-200 employeessimulated See all 5 comments
“The headline "Veeva Vault specialists" plus that line about "misconfigured Vault doesn't fail immediately — it fails six months later" told me exactly the problem: bad implementations show…” Show full quote
“The headline "Veeva Vault specialists" plus that line about "misconfigured Vault doesn't fail immediately — it fails six months later" told me exactly the problem: bad implementations show up as compliance/validation gaps down the line, which is literally our issue with Documentum support.”
IT Business Partner, Biotechnology · 1001-5000 employeessimulated “The FAQ "We have an internal IT team that manages our Vault day to day — where does Wolvio fit?" nails the reader down even further: companies that…” Show full quote
“The FAQ "We have an internal IT team that manages our Vault day to day — where does Wolvio fit?" nails the reader down even further: companies that already own Vault but lack release-management bandwidth or validation depth, which matches my situation exactly.”
Quality Systems Manager, Medical Devices · 51-200 employeessimulated “"A misconfigured Vault doesn't fail immediately — it fails six months later in a workflow that contradicts your SOPs, in validation documentation your QA team won't sign off…” Show full quote
“"A misconfigured Vault doesn't fail immediately — it fails six months later in a workflow that contradicts your SOPs, in validation documentation your QA team won't sign off on." That's a specific, credible failure mode and it's exactly my problem”
QA/QMS Manager, Pharmaceutical · 201-500 employeessimulated “a misconfigured Vault doesn't fail immediately — it fails six months later in a workflow that contradicts your SOPs”
Regulatory Operations Manager, Biotechnology · 501-1000 employeessimulated
Value
The standalone platform assessment reads as a credible low-risk entry point
3 of 15 · what worked
“That's a real, named deliverable, not just a promise, so it's worth a scoping call to see it. But before committing beyond that I'd need numbers: how long…” Show full quote
“That's a real, named deliverable, not just a promise, so it's worth a scoping call to see it. But before committing beyond that I'd need numbers: how long does a typical assessment take, what does it cost, and can they show me an anonymized sample output”
Regulatory Operations Manager, Biotechnology · 51-200 employeessimulated See all 3 comments
“A validated, audit-ready Vault QMS live on schedule with zero post-go-live surprises that make QA refuse to sign off — that's the single outcome that justifies the spend”
Clinical Operations Manager, Pharmaceutical · 501-1000 employeessimulated “their "standalone platform assessment" offering a clear written picture of "what is working, what carries risk, and what needs attention" is a genuinely low-risk way to test that…” Show full quote
“their "standalone platform assessment" offering a clear written picture of "what is working, what carries risk, and what needs attention" is a genuinely low-risk way to test that before committing money”
QA/QMS Manager, Pharmaceutical · 201-500 employeessimulated
Brand alignment
The tone reads as pharma-first and at times as agency copy rather than practitioner voice
2 of 15
“They sell to mid-size pharma/biotech primarily, with medtech as a secondary afterthought — the language defaults to "regulated environment," SOPs, QA sign-off, inspection readiness, which is pharma-flavored vocabulary…” Show full quote
“They sell to mid-size pharma/biotech primarily, with medtech as a secondary afterthought — the language defaults to "regulated environment," SOPs, QA sign-off, inspection readiness, which is pharma-flavored vocabulary even when they nod to medtech.”
Quality Systems Manager, Medical Devices · 51-200 employeessimulated See all 3 comments
“the hero section ("know vault inside out... not just a platform, as a practice") is agency copywriting, not a consultant talking, and that mismatch makes me trust the…” Show full quote
“the hero section ("know vault inside out... not just a platform, as a practice") is agency copywriting, not a consultant talking, and that mismatch makes me trust the FAQ section more than the top of the page”
QA/QMS Manager, Pharmaceutical · 201-500 employeessimulated “It's the opening phrases — "specialists who know vault inside out," "not just as a platform, as a practice" — abstract nouns stacked on abstract nouns with no…” Show full quote
“It's the opening phrases — "specialists who know vault inside out," "not just as a platform, as a practice" — abstract nouns stacked on abstract nouns with no verb telling me what they actually do on a Tuesday”
QA/QMS Manager, Pharmaceutical · 201-500 employeessimulated The copy demonstrates real operator knowledge of QA and RIM failure modes
2 of 15 · what worked
“The tone does feel like it was written for someone like me specifically — the line about a misconfigured Vault failing "six months later... by then, the implementation…” Show full quote
“The tone does feel like it was written for someone like me specifically — the line about a misconfigured Vault failing "six months later... by then, the implementation partner has moved on" is exactly the scar tissue a RIM lead mid-migration carries”
RIM Lead, Medical Devices · 1001-5000 employeessimulated See all 2 comments
“lines like "a misconfigured Vault doesn't fail immediately — it fails six months later in a workflow that contradicts your SOPs" show they know the actual failure mode…” Show full quote
“lines like "a misconfigured Vault doesn't fail immediately — it fails six months later in a workflow that contradicts your SOPs" show they know the actual failure mode QA/QMS people lose sleep over”
QA/QMS Manager, Pharmaceutical · 1001-5000 employeessimulated
05
How this works
Who we simulated (15 personas)
15 AI-simulated personas matched to your target market. Each answered independently, without seeing your goal, the scoring criteria, or each other’s answers. Attribution is role, industry and company size only.
Regulatory Operations ManagerBiotechnology · 51-200 employeesAsia
RIM LeadMedical Devices · 201-500 employeesNorth America
Clinical Operations ManagerPharmaceutical · 501-1000 employeesEurope
IT Business PartnerBiotechnology · 1001-5000 employeesAsia
Quality Systems ManagerMedical Devices · 51-200 employeesNorth America
QA/QMS ManagerPharmaceutical · 201-500 employeesEurope
Regulatory Operations ManagerBiotechnology · 501-1000 employeesAsia
RIM LeadMedical Devices · 1001-5000 employeesNorth America
Clinical Operations ManagerPharmaceutical · 51-200 employeesEurope
IT Business PartnerBiotechnology · 201-500 employeesAsia
Quality Systems ManagerMedical Devices · 501-1000 employeesNorth America
QA/QMS ManagerPharmaceutical · 1001-5000 employeesEurope
Regulatory Operations ManagerBiotechnology · 51-200 employeesAsia
RIM LeadMedical Devices · 201-500 employeesNorth America
Clinical Operations ManagerPharmaceutical · 501-1000 employeesEurope
Methodology
Every answer on this page was written by an AI model role-playing a buyer profile, scored on Wynter’s B2B Message Layers framework. The personas were sampled in code across role, industry, company size and behavioral traits; the model wrote only the answers. Scores arrive through fixed verdict categories and the counts are computed in our own code, so no number here was written by a model.
Score details: the count and the strength
The count is how many personas cleared the bar on each question. A yes can be unhesitating or come with reservations; the scorecard counts both as a yes, and this is the only place the difference is shown. Per layer:
- Clarity: 15 of 15, 13 without hesitation, 2 with reservations
- Relevance: 15 of 15, 5 without hesitation, 10 with reservations
- Value: 15 of 15, all with reservations
- Differentiation: 10 of 15, all with reservations
These answers are AI-simulated and directional. Validate anything you’re betting on with real buyers, your ICPs.
Your next 3 moves
- 1.Add a client proof block under the stats row with named or redacted engagements.
- 2.Add a line under the hero naming the roles you work with.
- 3.Add price range and a sample output link under the platform assessment.
See what real buyers say.
A detailed, section-by-section message test report from verified B2B professionals who are actually in-market for what you sell.
Trusted by
RetentionThis report is kept for 60 days, until 26 Dec 2026, then deleted along with the personas, their answers and everything derived from them. The link stays live for that whole period so it can be shared or revisited, and stops working afterwards.
The email address it was requested from is kept beyond that, because it subscribes you to the newsletter — that was the price of the report. You can unsubscribe in one click from any issue, which stops the email without affecting a report still inside its 60 days. The public report page never shows the requester’s address.
The email address it was requested from is kept beyond that, because it subscribes you to the newsletter — that was the price of the report. You can unsubscribe in one click from any issue, which stops the email without affecting a report still inside its 60 days. The public report page never shows the requester’s address.